Faisal Ghiath Sukhtian, Director at Outlook Therapeutics, Inc. (OTLK), bought 122,174 shares at $0.41 ($50K) on 2026-05-27, disclosed to the SEC on 2026-05-27.
Director Faisal Ghiath Sukhtian purchased 122,174 shares at $0.41 on May 27, 2026, marking the largest insider buy in the company's history. This accumulation occurs as the stock trades near its 52-week low, potentially reflecting confidence in the recent FDA appeal ruling.
The stock is currently trading at $0.394, just 3.66% above its 52-week low of $0.3801, despite a 75.53% decline from its 52-week high of $3.39.
The FDA granted Outlook Therapeutics an appeal on May 26, 2026, regarding its Lytenava drug, which triggered a pre-market surge. Additionally, the company is seeing broad sectoral optimism and strong institutional backing as reported on May 27, 2026.
The company faces execution risk following recent missed earnings estimates, including a -33.33% earnings surprise in Q2 2026. Furthermore, the stock has a short interest of 5.33% and a history of regulatory rejections, including a third CRL for ONS-5010 in January 2026.
Something here stands out, but not much.
| Filing → |
| OTLK | BUY | 2021-12-02 | $25K | — | Filing → |
| OTLK | BUY | 2021-04-20 | $18K | — | Filing → |
| OTLK | BUY | 2020-09-17 | $7K | — | Filing → |